全文获取类型
收费全文 | 36221篇 |
免费 | 2191篇 |
国内免费 | 110篇 |
专业分类
耳鼻咽喉 | 321篇 |
儿科学 | 1166篇 |
妇产科学 | 1011篇 |
基础医学 | 4949篇 |
口腔科学 | 616篇 |
临床医学 | 5926篇 |
内科学 | 6575篇 |
皮肤病学 | 598篇 |
神经病学 | 3444篇 |
特种医学 | 606篇 |
外科学 | 3122篇 |
综合类 | 403篇 |
一般理论 | 55篇 |
预防医学 | 4527篇 |
眼科学 | 468篇 |
药学 | 2119篇 |
中国医学 | 68篇 |
肿瘤学 | 2548篇 |
出版年
2023年 | 197篇 |
2022年 | 382篇 |
2021年 | 775篇 |
2020年 | 459篇 |
2019年 | 779篇 |
2018年 | 896篇 |
2017年 | 619篇 |
2016年 | 648篇 |
2015年 | 833篇 |
2014年 | 1171篇 |
2013年 | 1780篇 |
2012年 | 2654篇 |
2011年 | 2802篇 |
2010年 | 1528篇 |
2009年 | 1286篇 |
2008年 | 2540篇 |
2007年 | 2545篇 |
2006年 | 2565篇 |
2005年 | 2385篇 |
2004年 | 2305篇 |
2003年 | 2184篇 |
2002年 | 2041篇 |
2001年 | 220篇 |
2000年 | 151篇 |
1999年 | 298篇 |
1998年 | 412篇 |
1997年 | 367篇 |
1996年 | 326篇 |
1995年 | 279篇 |
1994年 | 271篇 |
1993年 | 253篇 |
1992年 | 166篇 |
1991年 | 137篇 |
1990年 | 133篇 |
1989年 | 128篇 |
1988年 | 106篇 |
1987年 | 112篇 |
1986年 | 90篇 |
1985年 | 107篇 |
1984年 | 155篇 |
1983年 | 157篇 |
1982年 | 194篇 |
1981年 | 167篇 |
1980年 | 159篇 |
1979年 | 93篇 |
1978年 | 74篇 |
1977年 | 81篇 |
1976年 | 60篇 |
1975年 | 53篇 |
1974年 | 68篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
11.
Theodore C. Bania MD MS Tom Ashar MD Gregory Press MD Patricia M. Carey MD 《Academic emergency medicine》2003,10(7):697-704
Long-term daily use of gamma-hydroxybutyrate (GHB) and related compounds has recently been associated with a withdrawal syndrome. To the best of the authors' knowledge, there are currently no animal models of GHB withdrawal. OBJECTIVES: The authors studied and described the effect of chronic dosing of GHB (3-6 days) on tolerance and withdrawal in a rat model. METHODS: Rats were administered GHB every three hours via intraperitoneal catheter. Groups of rats (2 per group) were dosed with GHB for either 3 (24 doses), 4 (32 doses), 5 (40 doses), or 6 (48 doses) days. The GHB dose was 0.25 g/kg for doses 1-8, 0.75 g/kg for doses 9-12, 1 g/kg for doses 13-16, 1.25 g/kg for doses 17-24, 1.5 g/kg for doses 25-32, 1.75 g/kg for doses 33-40, and 2 g/kg for doses 41-48. Following the last dose of GHB, the rats were scored using a 16-point ethanol intoxication-withdrawal scale rating spontaneous behaviors, response to handling, grooming, and neurological signs. Lower scores indicate intoxication, while higher scores indicate withdrawal. Scores were recorded at hours 0, 1, 2, 3, 4, 5, 6, 9, 12, and 24. RESULTS: Tolerance: Rats dosed with GHB for more days were less intoxicated one hour after their last GHB dose despite receiving higher doses. WITHDRAWAL: The scores for all rats dosed with GHB increased at hours 4 (p = 0.028), 5 (p = 0.037), 6 (p = 0.007), and 9 (p = 0.024) after the last dose, indicating withdrawal. The scores demonstrated a linear increase dependent upon the number of days of GHB dosing at hours 3 (p < 0.000), 4 (p = 0.004), 5 (p = 0.002), and 12 (p = 0.039) as well as prior to the last dose at hour 0 (p = 0.000). No rats developed seizures. CONCLUSIONS: Tolerance and mild withdrawal in rats can be induced by administering intraperitoneal GHB every three hours for 3-6 days. More prolonged dosing and higher doses of GHB may be necessary to induce severe withdrawal. 相似文献
12.
The molecular and clinical impact of hepatocyte growth factor, its receptor, activators, and inhibitors in wound healing 总被引:1,自引:0,他引:1
Kevin Conway MRCS ; Patricia Price PhD ; Keith G. Harding FRCS ; Wen G. Jiang MD 《Wound repair and regeneration》2006,14(1):2-10
Wound healing involves a number of cellular and molecular events, many of which are controlled by soluble growth factors. In the process of healing, hepatocyte growth factor, a cytokine known to act as mitogen, motogen, and morphogen, has been postulated to play multiple roles during several stages of this complex biological process. Produced primarily by stromal fibroblasts, hepatocyte growth factor regulates angiogenesis, vascular permeability, cell migration, matrix deposition and degradation, and other biological processes. The current article discusses recent progress in understanding the multiple roles played by this growth factor in tissue repair. 相似文献
13.
Daniel D. Billadeau Subrha Chatterjee Patricia Bramati Raghavakaimal Sreekumar Vijay Shah Karen Hedin Raul Urrutia 《Journal of gastrointestinal cancer》2006,37(4):110-119
CXCL12 and its receptor, CXCR4, are emerging as promising targets for modulating growth, angiogenesis, and metastasis in several human cancers. Indeed, blocking the receptor is sufficient to prevent metastasis and angiogenesis in experimental breast cancer xenografts. Recently, the biological effect of the CXCR4 in pancreatic cancer, one of the most deadly neoplastic diseases, has been reported. However, the molecular mechanism by which CXCR4 contributes to these properties is not completely understood. In this paper, we characterize the signaling pathways activated by CXCR4 in pancreatic cancer. We show that after CXCR4 activation, EGFR becomes tyrosine phosphorylated, and the kinase activity of this receptor, together with the activation of MMPs, Src, and PI3-Kinase, is required for CXCR4-mediated ERK activation. Analysis of this cascade in pancreatic cancer cells revealed that the ERK-mediated pathway regulates genes involved in angiogenesis, such as VEGF, CD44, HIF1α, and IL-8. Furthermore, ERK blockage inhibits the migration and tube formation of endothelial cells induced by CXCL12. Considering that inhibitors for several components of this pathway, including CXCR4 itself, are at different stages of clinical trials, this study provides theoretical justification for the clinical testing of these drugs in pancreatic cancer, thus extending the list of potential targets for treating this dismal disease. 相似文献
14.
Thomas James Zirpoli Patricia Mulhearn Blasco 《Journal of developmental and physical disabilities》1988,1(1):69-77
Current medical procedures used in prenatal screening and diagnosis of handicapping conditions are reviewed. These strategies include ultrasound, amniocentesis, chorionic villus biopsy, restriction enzyme analysis, maternal serum analysis, fetoscopy, and fetal serum analysis. Along with an explanation of each method, advantages, disadvantages, and risks involved with each are provided. An understanding of these procedures by medical and educational personnel is encouraged, and the potential benefits of prenatal identification of handicapping conditions are emphasized. 相似文献
15.
16.
17.
Cheryl Wallerstedt RNC MS Patricia Higgins RN PhD 《Journal of obstetric, gynecologic, and neonatal nursing : JOGNN / NAACOG》1996,25(5):389-400
Society often expects mothers and fathers to share equally in the perinatal grief process because the child was a common bond between them. Unfortunately, in perinatal grief, this is not always the case. The mother and the father can experience incongruent grieving and use discordant coping mechanisms. It is important to evaluate these differences to facilitate communication between the distraught parents. Improved communication can in turn facilitate the grieving process. 相似文献
18.
19.
20.
Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies
Bayard L. Powell Hyman B. Muss Robert L. Capizzi Mary E. Caponera Douglas R. White Patricia J. Zekan James N. Atkins Don V. Jackson Jr. Frederick Richards II John B. Craig Julia M. Cruz Charles L. Spurr 《Cancer chemotherapy and pharmacology》1987,19(3):250-252
Summary Cytosine arabinsodie (ara-C) and etoposide (VP-16) display synergy in the laboratory. Twenty-six patients participated in a phase I study of high-dose ara-C in combination with VP-16. The dose of VP-16 was held constant at 50 mg/m2 as an intermittent infusion over 33 h; escalating doses of ara-C were given as infusions during hours 9–12 and 21–24. Myelosuppression was the dose-limiting toxicity and occurred with doses considerably less than those expected from studies of the two drugs as single agents. The suggested initial doses for phase II trials with this schedule are 750 mg/m2×2 doses of ara-C and 50 mg/m2 of VP-16. Nonhematologic toxicity was minimal; therefore, further dose escalation is feasible in patients in whom myelosuppression is acceptable.Supported in part by grants from the National Cancer Institute (CA-12197 and CA-09422) and the American Cancer Society CF-85-182 相似文献